Jaroslav Roh

8PUBLICATIONS
28CO-AUTHORS
Haematological tumoursGene and molecular therapyBiologically active moleculesCancer therapy (excl. chemotherapy and radiation therapy)Cheminformatics and quantitative structure-activity relationships
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Jul 23, 2026
Analysis of gene expression changes upon topobexin treatment and TOP2B-knockout in hiPSC-derived cardiomyocytes.

|Oct 07, 2025
Scaffold Hopping in Tuberculosis Drug Discovery: Principles, Applications, and Case Studies.

Ondrej Kovar, Martin Kufa, Vladimir Finger

|Dec 29, 2023
Both Nitro Groups Are Essential for High Antitubercular Activity of 3,5-Dinitrobenzylsulfanyl Tetrazoles and 1,3,4-Oxadiazoles through the Deazaflavin-Dependent Nitroreductase Activation Pathway.

Galina Karabanovich, Viktória Fabiánová, Anthony Vocat

|Sep 23, 2021
Clinically Translatable Prevention of Anthracycline Cardiotoxicity by Dexrazoxane Is Mediated by Topoisomerase II Beta and Not Metal Chelation.

Eduard Jirkovský, Anna Jirkovská, Hana Bavlovič-Piskáčková

|Mar 22, 2021
Structure-Activity Relationship Study of Dexrazoxane Analogues Reveals ICRF-193 as the Most Potent Bisdioxopiperazine against Anthracycline Toxicity to Cardiomyocytes Due to Its Strong Topoisomerase IIβ Interactions.

Anna Jirkovská, Galina Karabanovich, Jan Kubeš

|Apr 08, 2020
Investigation of Structure-Activity Relationships of Dexrazoxane Analogs Reveals Topoisomerase IIβ Interaction as a Prerequisite for Effective Protection against Anthracycline Cardiotoxicity.

Petra Kollárová-Brázdová, Anna Jirkovská, Galina Karabanovich

Pageof 2

Frequent Collaborators

3 joint publications

Petra Štěrbová-Kovaříková

3 joint publications

Anna Jirkovská

3 joint publications

Galina Karabanovich

3 joint publications

Jan Kubeš